ALK and neoplasm: The ALK IHC method determines whether tumor cells are harboring an ALK fusion using an antibody directed to the C-terminal ALK protein, but unlike FISH tests, it has been reported to show not only positive results in patients with ALK fusion–positive cancer but also false-negative errors in some patients who actually have ALK fusion–positive cancer [3, 6–8].